CMP Pharma is the innovator and leading provider of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia, a condition characterized by an abnormally high level of potassium in the blood.

  • Three-year product shelf life: 473 mL (Pint), 60mL Unit Dose
  • Two-year product shelf life: 120 mL enema kit
  • Store at controlled room temperature, 20°C -25°C (68°F -77°F), with short excursions permitted at 15°C -30°C
  • Available in 473 mL (Pint), 60 mL unit dose, and 120 mL enema kit
  • Manufactured at our facility in Farmville, NC

Download SPS® Suspension Packaging Insert

Download SPS Suspension SDS

Illustration of CMP Pharma SPS Suspension Bottles

What is hyperkalemia?

Hyperkalemia is a condition in which the concentration of potassium in the blood is elevated.

While most cases of hyperkalemia are mild, severe hyperkalemia is a medical emergency and can result in sudden death through cardiac arrhythmia or irregular heartbeat. When not recognized and treated properly, severe hyperkalemia results in a mortality rate of nearly 67%. Hyperkalemia is a fairly common blood condition and is diagnosed in up to 8% of U.S. hospitalized patients.

Most cases of hyperkalemia are caused by disorders that reduce kidney function, such as diabetes and cardiovascular disease. Hyperkalemia can also be caused by bodily injury and by certain medications, including non-steroidal anti-inflammatory drugs (e.g. aspirin and ibuprofen) and ACE Inhibitors, as well as transcellular shifts of potassium into the bloodstream, often caused by metabolic acidosis.